Aligos Therapeutics Inc. (ALGS)
Summary
Aligos Therapeutics, Inc. (ALGS) Presents at Jefferies London Healthcare Conference 2025 Transcript
Aligos Therapeutics, Inc. ( ALGS ) Jefferies London Healthcare Conference 2025 November 17, 2025 10:00 AM EST Company Participants Lawrence Blatt - CEO, President & Chairman of the Board Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Presentation Yuxi Dong Jefferies LLC, Research Division All right. Let's get started, and good afternoon, everyone.
Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 983.2% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $2.35. This compares to earnings of $0.75 per share a year ago.
Aligos Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 83,055 | $719,256 | $452,234.47 | -$267,021.53 | -37.12% |
| NM Nir Messafi Deep Track Capita LLP | 444,110 | $3.76M | $2.42M | -$1.35M | -35.75% |
 Drew Phillips Fortitude Family Office LLC | 68 | $505 | $390.32 | -$114.68 | -22.71% |
 Andrew Kirchner ELEVATION WEALTH PARTNERS, LLC | 4 | $35 | $21.76 | -$13.24 | -37.83% |
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 950 | $7,059 | $5,016 | -$2,043 | -28.94% |
Aligos Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DB Daniel Brims Lake Street | 11,482.42 | $60,708.36 | $59,134.46 | -$1,573.9 | -2.59% |
Aligos Therapeutics Inc. (ALGS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aligos Therapeutics Inc. ever had a stock split?
Aligos Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Lawrence Blatt CEO | NASDAQ (CM) Exchange | 01626L204 CUSIP |
| US Country | 82 Employees | - Last Dividend | 19 Aug 2024 Last Split | 16 Oct 2020 IPO Date |
Overview
Aligos Therapeutics, Inc. is a pioneering clinical-stage biopharmaceutical company that embarks on the mission of developing novel therapeutics aimed at fulfilling the unmet medical needs prevalent in viral and liver diseases. Incorporated in 2018 and based in South San Francisco, California, the company strategically focuses its efforts on the invention and progression of treatments that could potentially alter the current therapeutic landscape. By engrossing in research and development activities, Aligos Therapeutics is at the forefront of addressing complex health issues, particularly in the domain of non-alcoholic steatohepatitis (NASH), chronic hepatitis B (CHB), and coronavirus-related conditions. Engaging in a series of collaboration agreements with leading academic and corporate entities, the company reinforces its scientific and commercial footprint across the globe, signifying a substantial commitment towards fostering innovative healthcare solutions.
Products and Services
- ALG-055009
A hallmark of Aligos Therapeutics’ portfolio, ALG-055009 emerges as a small molecule THR-ß agonist currently under evaluation in a Phase 2a clinical trial. This cutting-edge therapeutic candidate is specifically designed to treat non-alcoholic steatohepatitis (NASH), marking a significant stride towards addressing this challenging liver disease.
- ALG-000184
This innovative capsid assembly modulator has successfully completed a Phase 1b clinical trial, showcasing its potential in the treatment of chronic hepatitis B (CHB). As a testament to the company’s dedication to combating viral liver diseases, ALG-000184 exemplifies a proactive approach to CHB therapy.
- ALG-125755
In the realm of RNA-based therapeutics, ALG-125755 stands out as a siRNA (small interfering RNA) drug candidate. Currently assessed in a Phase I clinical trial, this product targets chronic hepatitis B (CHB), reinforcing Aligos Therapeutics’ commitment to leveraging cutting-edge biotechnology for disease management.
- ALG-097558
Reflecting a versatile and responsive R&D strategy, ALG-097558 is an investigational drug poised in a Phase 2 clinical trial aimed at treating coronavirus. This intervention underscores the company’s agile response to emergent global health crises and its dedication to public health.
Integral to its innovative framework, Aligos Therapeutics has forged strategic partnerships and licensing agreements. Collaborations with entities such as Merck for oligonucleotide therapy in NASH, Emory University for HBV capsid assembly modulator technology, Luxna Biotech for HBV genome-targeting oligonucleotides, and Katholieke Universiteit Leuven for coronavirus protease inhibitors, alongside a clinical partnership with Xiamen Amoytop Biotech, amplify the company’s research capacity and commercial potential in addressing complex viral and liver diseases.
